Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1984 Feb;49(2):117–122. doi: 10.1038/bjc.1984.22

Prospects for the future in the management of carcinoma of the breast: the biological fall out from clinical trials.

M Baum
PMCID: PMC1976697  PMID: 6696816

Full text

PDF
117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baum M., Brinkley D. M., Dossett J. A., McPherson K., Patterson J. S., Rubens R. D., Smiddy F. G., Stoll B. A., Wilson A., Lea J. C. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet. 1983 Aug 20;2(8347):450–450. doi: 10.1016/s0140-6736(83)90406-3. [DOI] [PubMed] [Google Scholar]
  2. Baum M., Fisher B. Macrophage production by the bone marrow of tumor-bearing mice. Cancer Res. 1972 Dec;32(12):2813–2817. [PubMed] [Google Scholar]
  3. Bennett A., Berstock D. A., Carroll M. A., Stamford I. F., Wilson A. J. Breast cancer, its recurrence, and patient survival in relation to tumor prostaglandins. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:299–302. [PubMed] [Google Scholar]
  4. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  5. Cooper R. G., Holland J. F., Glidewell O. Adjuvant chemotherapy of breast cancer. Cancer. 1979 Sep;44(3):793–798. doi: 10.1002/1097-0142(197909)44:3<793::aid-cncr2820440302>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  6. Coughlin S. R., Moskowitz M. A., Zetter B. R., Antoniades H. N., Levine L. Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor. Nature. 1980 Dec 11;288(5791):600–602. doi: 10.1038/288600a0. [DOI] [PubMed] [Google Scholar]
  7. DEVITT J. E. THE SIGNIFICANCE OF REGIONAL LUMPH NODE METASTASES IN BREAST CARCINOMA. Can Med Assoc J. 1965 Aug 14;93:289–293. [PMC free article] [PubMed] [Google Scholar]
  8. Fisher B., Redmond C., Fisher E. R. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology--an overview of findings. Cancer. 1980 Aug 15;46(4 Suppl):1009–1025. doi: 10.1002/1097-0142(19800815)46:4+<1009::aid-cncr2820461326>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  9. Freiman J. A., Chalmers T. C., Smith H., Jr, Kuebler R. R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep 28;299(13):690–694. doi: 10.1056/NEJM197809282991304. [DOI] [PubMed] [Google Scholar]
  10. Kon O. L. An antiestrogen-binding protein in human tissues. J Biol Chem. 1983 Mar 10;258(5):3173–3177. [PubMed] [Google Scholar]
  11. Meyer J. S., Rao B. R., Stevens S. C., White W. L. Low incidence of estrogen receptor in breast carcinomas with rapid rates of cellular replication. Cancer. 1977 Nov;40(5):2290–2298. doi: 10.1002/1097-0142(197711)40:5<2290::aid-cncr2820400541>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  12. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer. 1976 Dec;34(6):585–612. doi: 10.1038/bjc.1976.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Priestman T., Baum M., Jones V., Forbes J. Treatment and survival on advanced breast cancer. Br Med J. 1978 Dec 16;2(6153):1673–1674. doi: 10.1136/bmj.2.6153.1673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rose D. P., Davis T. E. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet. 1977 Jun 4;1(8023):1174–1176. doi: 10.1016/s0140-6736(77)92716-7. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES